How best to determine causative pathogens of pneumonia by unknown
PneumoniaMurdoch Pneumonia  (2016) 8:1 DOI 10.1186/s41479-016-0004-zCOMMENTARY Open AccessHow best to determine causative
pathogens of pneumonia
David R. MurdochAbstract
The biggest recent development in pneumonia diagnostics has been the increased availability and use of nucleic
acid detection assays, although this change has brought with it new challenges about the interpretation of positive
results. Recognition of the existence of the lung microbiome has challenged the traditional views of pneumonia
pathogenesis and may provide the opportunity for new diagnostic tools that are focused on more than just detection
of specific known pathogens.
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pneumonia diagnostics [1]. This is a challenging area.
Historically, even with the best of methods, we have
been unable to define a causative pathogen in a signifi-
cant proportion of pneumonia episodes, especially in
children. The impact of suboptimal diagnostics extends
beyond individual patient care, also limiting our ability
to assess interventions such as vaccines. Timed to coin-
cide with the first World Pneumonia Day, our com-
mentary tried to encourage a fresh look at pneumonia
diagnostics. How has the world changed in the past
seven years?
In 2009, we were still reliant on traditional diagnostics
based on microscopy and culture—methods that had been
around for decades. There had been modest advances in
antigen detection methods, limited mainly to pneumococ-
cal disease in adults and Legionnaires’ disease. Nucleic
acid detection tests (NATs), such as polymerase chain
reaction (PCR), had been established for all major pneu-
monia pathogens and were the single biggest development
in the area, although widespread uptake by diagnostic
laboratories had been slow. We highlighted several issues
that needed addressing in order to move forward. The
inability to obtain good quality specimens from the lower
respiratory tract was a fundamental problem. Many diag-
nostic methods, such as blood culture, had poor diagnos-
tic sensitivity, while the assessment of diagnostic accuracyCorrespondence: david.murdoch@otago.ac.nz
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tor (“gold”) standards. Importantly, assigning causation
was a struggle. Many pneumonia pathogens can also be
asymptomatic colonisers of the upper respiratory tract, so
distinguishing innocent bystanders from true pathogens
can be challenging when detected in clinical specimens
from non-sterile sites, such as expectorated sputum. We
emphasised the need to look beyond technology, and the
importance of assessing diagnostic performance within
clinical and epidemiologic contexts. We were also hopeful
for innovative new approaches.
So, what does the situation look like in 2016? A major
change for diagnostic laboratories over the past seven
years has been the increased availability of commercial
NATs for respiratory pathogens. There are now many
choices, typically in multiplex format, and the range
continues to expand. Indeed, debate has started about
whether these large multiplex panels should be subjected
to restricted use in order to ensure appropriate use [2].
Furthermore, the successful deployment around the
world of the Xpert® MTB/RIF assay (Cepheid, United
States of America) for tuberculosis diagnostics has dem-
onstrated the potential use of NATs beyond well-equipped
laboratories and into resource-limited settings [3]. Despite
their increased availability, NATs do not yet have clearly
established roles for some major pneumonia pathogens. In
particular, the inability to reliably distinguish Streptococcus
pneumoniae carriage from disease when testing respira-
tory specimens is a major limitation, although setting
thresholds based on bacterial load has shown promise indistributed under the terms of the Creative Commons Attribution 4.0
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lance programmes [5], PCR testing of blood specimens for
S. pneumoniae is not an established test for diagnosing
pneumococcal pneumonia in individual patients due to
uncertainty about diagnostic accuracy across different
populations.
Therefore, in the context of pneumonia, NATs are still
mainly useful for detection of non-colonising bacteria,
such as Legionella species [6] and Mycobacterium tuber-
culosis [3], and for respiratory viruses. Even then, case-
control studies have demonstrated the need for caution
with the interpretation of respiratory virus test results,
as positive results have been found to be as common in
healthy controls as among pneumonia patients, espe-
cially for viruses other than influenza viruses, respiratory
syncytial virus, and human metapneumovirus [7, 8]. While
the development of cheaper and more user-friendly plat-
forms will always be welcome, there needs to be a change
in emphasis away from simply detecting specific organ-
isms in a given specimen to also demonstrating that those
organisms are actually causing pneumonia. The broader
approach of next generation sequencing may provide
novel insights into pneumonia aetiology, but has yet to
show added advantage as a diagnostic tool [9].
A major recent revelation has been recognition of the
lung microbiome [10]. Until recently, the lungs in health
were regarded as sterile. The use of modern culture-
independent techniques has not supported this notion,
consistently finding evidence of bacteria in the lower air-
ways [10]. This important realisation, along with the in-
creasing recognition that bacteria and viruses frequently
interact in the causative pathway to pneumonia [11], has
challenged our traditional paradigm of pneumonia patho-
genesis. In the new paradigm, dominant species emerge
from the lung ecosystem in pneumonia through uncertain
mechanisms, polymicrobial pneumonia may be common
[12], and the bacterial versus viral pneumonia concept is
naïve and unsophisticated. There is still much to under-
stand, but there is a clear indication that new diagnostic
tools for pneumonia should not just be focused on detec-
tion of specific known pathogens.
No major new innovative approaches to pneumonia
diagnostics have appeared since 2009. The potential for
breath analysis has still not been realised and is the sub-
ject of ongoing investigation by many research groups
[13, 14]. There have also been no major new break-
throughs in the biomarker world to aid the aetiologic
diagnosis of pneumonia. While there is some evidence
that antibiotic management of pneumonia may be
guided by blood procalcitonin levels [15], it is unclear
whether procalcitonin is functioning as a marker for
bacterial pneumonia or as a marker of disease severity.
This is particularly pertinent as we move away from the
simplistic bacterial versus viral pneumonia paradigm. Itis possible that the answer may lie with certain combina-
tions of protein biomarkers that may have greater utility
for determining microbial aetiology in pneumonia [16],
or that biomarkers are better used for purposes other
than for determining the cause of pneumonia [17].
The findings of one of the world’s largest pneumonia
aetiology studies will be published in 2016 with great an-
ticipation. The Pneumonia Etiology Research for Child
Health (PERCH) project is a seven-country case-control
study, which is focused on the causes of severe pneumo-
nia in young children from developing countries [18].
There is great interest in PERCH’s experience deploying
state of the art diagnostics at each study site. However,
one of the most novel aspects of PERCH is the use of
sophisticated statistical modelling techniques to help in-
terpret diagnostic test results. Partially latent class
models have been designed for estimating the population
aetiology distribution and the individual aetiology prob-
abilities for specific pneumonia pathogens [19]. This ap-
proach endeavours to overcome the known limitations
of diagnostic testing, and has never before been so ex-
tensively applied to the aetiology of an infectious disease.
It remains to be seen what reception this approach will
receive from the scientific community.
For the diagnostic laboratory, there have been only
modest changes in the approach to determining the causa-
tive pathogens of pneumonia over recent years. However,
we have entered a new age that could well increase the
pace of development. By opening our minds to new para-
digms of pneumonia pathogenesis and increasing our
understanding of the lung microbiome in health and dis-
ease, additional diagnostic tools are likely to appear that
will help better guide the management of pneumonia.
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